Home » Pharma » Seishima R et al. 2016; Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9+ cancer stem cells in ulcerative colitis-related cancer; Clin. Res. Hepatol. Gastroenterol. 40(4):487-93 » Sulfasalazin01917